Navigation Links
Cardiometabolic Health Congress Expert Faculty Weigh in on FDA Advisory Panel Recommendation for Novel Weight-Loss Medication

BOSTON, Feb. 28, 2012 /PRNewswire/ -- The Food and Drug Administration advisory panel voted on Wednesday, Feb. 22, 2012, in favor of recommending that the FDA approve the prescription obesity drug Qnexa.  If approved, this will be the first time in more than a decade that a prescription weight-loss medication receives FDA approval.  This landmark recommendation prompted the 2012 Cardiometabolic Health Congress (CMHC) expert faculty to weigh in on the implications of the potential approval of this novel obesity medication.

"I am pleased that the FDA advisory panel has been able to see a way forward to support therapies that will help patients and clinicians confront the obesity epidemic. While pharmacotherapy is not appropriate for everyone, it is important to have options to help patients," said Richard Pratley, MD, professor of medicine and director of the Diabetes and Metabolism Translational Medicine Unit at the University of Vermont College of Medicine in Burlington, VT.

Robert H. Eckel, MD, co-chair of the 2012 CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus, said, "I think the decision was a good one and is important for the academic and medical educational missions related to obesity and cardiovascular disease." 

"It is a very interesting development and a bit surprising," said Deepak L. Bhatt, MD, Chief of Cardiology, VA Boston Healthcare System, associate professor of medicine at Harvard Medical School, and senior investigator, TIMI Study Group.  He added, "I still think that a large study evaluating cardiovascular safety is needed."

The Chief Scientific Officer for the Association of Black Cardiologists and professor of clinical medicine at Tulane University School of Medicine, Keith C. Ferdinand, MD, cautioned that, "The fight against obesity needs to be multifactorial, including new medications. As a cardiologist, however, I consider it paramount that all clinicians remember to monitor our patients closely for cardiac risks, including heart rate and blood pressure, and not just treat obesity as a cosmetic concern."

Harold Bays, MD, medical director and president, Louisville Metabolic and Atherosclerosis Research Center, Inc., stated, "This [FDA advisory panel] decision validates the emerging recognition that adiposity, or fat weight gain, creates adipose tissue dysfunction or 'sick fat' which directly and indirectly contributes to metabolic disease.  As importantly, the Qnexa development program objectively supports how fat weight reduction improves adipose tissue function, effectively treats the metabolic and immune abnormalities of 'sick fat,' and thus improves the most common metabolic diseases encountered in clinical practice, such as elevated glucose, blood pressure, and dyslipidemia - all major cardiovascular disease risk factors."

The Centers for Disease Control and Prevention state that over 35 percent of American adults are obese, with 5 percent being considered morbidly obese. In addition, 33 percent of American adults are overweight.  In response to this obesity epidemic, the CMHC, the most influential U.S.-based medical and scientific conference in its field, gathers over 50 world-renowned experts in cardiometabolic health each year to educate clinicians on current strategies for the prevention, diagnosis and management of obesity, type 2 diabetes, atherosclerosis, hypertension, dyslipidemia, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

"It is striking that the CMHC has become the undisputed leader in conferences that address the most important metabolic derangements of our time, due largely to the strength of the faculty and their interactions with an engaged audience," said James Gavin III, MD, PhD, CEO and Chief Medical Officer of Healing Our Village, Inc., and clinical professor of medicine, Emory University School of Medicine.

The 7th Annual CMHC will convene Oct. 10-13, 2012 in Boston, MA; it is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP.

For more information, contact Dina Kouveliotes at or 877.571.4700 or visit

SOURCE Cardiometabolic Health Congress
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
(Date:11/30/2015)... 2015 iCAD, Inc. (Nasdaq: ICAD ... latest solutions for advanced image analysis and workflow ... the Radiological Society of North American (RSNA) 2015 ... from November 29 to December 4, 2015. The ... an automated breast density assessment solution, PowerLook® Advanced ...
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... Kingdom , Nov. 30, 2015 ... a further 20 TrueBeam™ machines from Varian Medical ... an ongoing program to replace older machines and ... in the UK,s public hospitals. The order, placed ... and 50 licenses for Varian,s RapidArc® and Eclipse™ ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Support Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, ... seen over 60% growth from 2014. Throughout 2015, the company has completed ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with ... as a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: ... surgery and treatment of glaucoma and cataracts, and how a visit with his grandmother ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
(Date:11/30/2015)... ... 30, 2015 , ... Since its inception, Seniors Guide has ... assisted living and all other retirement options. Support for issues surrounding the senior ... a top priority. , So it’s no surprise that every November, Seniors ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. Whether ... among us. It is your perspective, however, that determines how you view death in ... Sky understands that she may see death more frequently than most. As she was ...
Breaking Medicine News(10 mins):